Nurix Therapeutics, INC. (NRIX) — 8-K Filings

All 8-K filings from Nurix Therapeutics, INC.. Browse 21 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (21)

8-K Filing — Apr 8, 2026
8-K Filing — Dec 9, 2025
8-K Filing — Nov 10, 2025
Nurix Therapeutics Files 8-K — Oct 22, 2025 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on October 22, 2025, reporting other events and financial statements. The filing does not contain specific details about n
Nurix Therapeutics Files 8-K — Oct 22, 2025 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on October 22, 2025, reporting on other events and financial statements. The filing does not contain specific details abou
Nurix Therapeutics Files 8-K — Sep 3, 2025 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on September 3, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the
Nurix Therapeutics Names New CEO, Restructures Leadership — Aug 22, 2025 Risk: medium
Nurix Therapeutics, Inc. announced on August 19, 2025, changes in its executive and board leadership. Dr. G. Jonah Wilson has been appointed as the new Chief Ex
Nurix Therapeutics Files 8-K — Jun 12, 2025 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements and Exh
Nurix Therapeutics Files 8-K on Shareholder Votes & Exhibits — May 19, 2025 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on May 19, 2025, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The filin
Nurix Therapeutics Appoints New CMO, Director — Mar 13, 2025 Risk: low
Nurix Therapeutics, Inc. announced on March 11, 2025, the appointment of Dr. Robert L. Kirk as Chief Medical Officer and the election of Ms. Jennifer L. Jones t
Nurix Therapeutics Files 8-K on Financials — Jan 13, 2025 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation F
Sanofi to Acquire Nurix Therapeutics for $2.4 Billion — Dec 10, 2024 Risk: medium
Nurix Therapeutics, Inc. announced on December 9, 2024, that it has entered into a definitive agreement to be acquired by Sanofi for approximately $2.4 billion.
Nurix Therapeutics Files 8-K — Oct 31, 2024 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on October 31, 2024, reporting other events and financial statements. The filing does not contain specific financial figur
Nurix Therapeutics Appoints New CMO, Adds Director — Oct 16, 2024 Risk: medium
Nurix Therapeutics, Inc. announced on October 15, 2024, the appointment of Dr. Robert L. Kirk as Chief Medical Officer and the election of Ms. Jennifer L. D. Go
Nurix Therapeutics Files 8-K Disclosure Update — Sep 5, 2024 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on September 5, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
Sanofi to Acquire Nurix Therapeutics for $2.3 Billion — Jun 17, 2024 Risk: medium
Nurix Therapeutics, Inc. announced on June 16, 2024, that it has entered into a definitive agreement to be acquired by Sanofi for approximately $2.3 billion. Th
Nurix Therapeutics Files 8-K on Shareholder Votes and Financials — May 21, 2024 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on May 20, 2024, to report on the submission of matters to a vote of security holders and financial statements. The filing
Nurix Therapeutics Announces Material Definitive Agreement — Apr 12, 2024 Risk: medium
On April 11, 2024, Nurix Therapeutics, Inc. announced a material definitive agreement, indicating a significant development for the company. The filing also inc
Nurix Therapeutics Files 8-K — Apr 9, 2024 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on April 9, 2024, reporting other events and financial statements. The filing details the company's principal executive of
Nurix Therapeutics Files 8-K — Mar 11, 2024 Risk: low
Nurix Therapeutics, Inc. filed an 8-K on March 11, 2024, to report other events and financial statements. The filing does not contain specific details about new
Nurix Therapeutics Files 8-K for Regulatory Disclosure & Exhibits — Jan 8, 2024
Nurix Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD and to include financial statements and exhibits

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX